ArticleHIV medicine2026
Effect of dolutegravir on 'Life's Simple 7' cardiovascular risk factors: A longitudinal analysis from Tanzania.
Article in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveWe sought to investigate the differences and changes over time in Life's Simple 7 (LS7) and Pooled Cohort Equation (PCE) scores for cardiovascular diseases (CVD) risk by HIV status in the Mwanza HIV&CVD Cohort from three outpatient, facility-based HIV clinics in urban Tanzania.
designLongitudinal comparative cohort study of people with HIV and people without HIV.
methodsPeople with HIV were enrolled at HIV diagnosis before antiretroviral therapy (ART) initiation and followed after 2 years of dolutegravir (DTG) exposure. The differences LS7 metrics by HIV status were measured. Each LS7 metric was categorized as ideal (2 points), intermediate (1 point) and poor (0 point). PCE risk score was categorized as low (<5%), intermediate (5% to <7.5%) and high (≥7.5%). Changes over time in total LS7 score, individual LS7 metrics and PCE scores were examined in people with HIV from the pre-ART to post-DTG visits using ordinal logistic mixed-effects regression.
resultsA total of 832 (402 people with HIV/430 people without HIV) participants were included in this analysis. Mean age was 39 (SD 10) years and 70% were female. At the post-DTG visit, mean LS7 score was 10.5 (SD 1.5), 44% of participants had ideal cardiovascular health (CVH), and mean PCE score was 2.3% (SD 3.0%). People with HIV versus people without HIV had higher odds of ideal blood pressure (BP) (adjusted odds ratio [aOR] = 1.50, 95% confidence interval [CI]: 1.14, 1.97), but 40% lower odds of achieving ideal physical activity (PA) (aOR = 0.60, 95% CI: 0.46, 0.79) during the post-DTG visit. People with HIV had a smaller increase in ideal BP compared to people without HIV, despite higher overall ideal BP at both visits. Most participants had a low PCE risk, though three times higher in males compared to females.
conclusionTraditional CVD risk factors like BP and PA remain similar by HIV status during the first 2 years of DTG exposure. Further work is needed to encourage PA among people with HIV and incorporate BP monitoring into routine HIV care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.